期刊文献+

血清CEA水平与乳腺癌的转移 被引量:6

Analysis of correlation between serum CEA level and metastases of breast cancer
原文传递
导出
摘要 目的:研究乳腺癌血清CEA与癌灶转移的关系,并比较其在不同器官转移中的阳性率差异。方法:采用美国Beckman Coulter ACCESS全自动微粒子化学发光免疫分析仪检测1729个乳腺癌转移患者和9262个乳腺癌未转移患者的血清CEA水平。结果:乳腺癌转移患者血清CEA大于5.0为820例,阳性率为:820/1729=47.43%;乳腺癌未转移患者血清CEA大于5.0为837例,其阳性率为:837/9247=9.05%;单纯合并脑、肝、骨、肺、淋巴结转移的患者CEA阳性率分别为56%、48.11%、45.45%、34.26%、18.45%;结论:乳腺癌转移患者血清CEA阳性率高于未转移患者,乳腺癌分别发生脑、肝、骨、肺转移的CEA阳性率间无差别,但都高于乳腺癌淋巴结转移的患者,因此CEA确实可作为乳腺癌病情判断及预后的监测指标。 Objective:To study the correlation between serum CEA level and metastasis of breast cancer,as well as the positive rates difference of CEA among different single organ metastasis in breast cancer.Methods: Serum CEA levels were detected with Beckman Coulter ACCESS chemiluminescent immunoassay in 1729 patients with breast cancer metastasis and 9262 patients without breast cancer metastasis.Results: The positive rate of CEA in the group of metastasis breast cancer patients was 47.43%,while the positive rate of CEA in the group of non-metastasis breast cancer patients was 9.05%.The positive rates of CEA in breast cancer patients complicated by different single organ metastasis were 56% for the brain,48.11% for the liver,45.45% for the bone,34.26% for the lung and 18.45% for the lymph nodes separately.Conclusion: The positive rate of CEA in patients with breast cancer metastasis was higher than that in patients without breast cancer metastasis.There is no significant difference in the positive rate of CEA among all the breast cancer patients with single organ metastasis except the patients with lymph nodes metastasis,while the latter was lower.So CEA can be truly an effective indicator for evaluating the prognosis of breast cancer.
机构地区 解放军第
出处 《中国卫生检验杂志》 北大核心 2012年第12期2927-2928,共2页 Chinese Journal of Health Laboratory Technology
关键词 乳腺癌 CEA 转移 Breast Cancer Carcinoembryonic antigen Metastasis
  • 相关文献

参考文献4

二级参考文献12

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:32
  • 2杨素芬.癌抗原125测定在盆腔肿块鉴别诊断中的意义[J].中国基层医药,2005,12(4):473-474. 被引量:1
  • 3陈竺.全国第三次死因回顾抽样调查报告[M].北京:中国协和医科大学出版社,2008:11-12.
  • 4赵平,陈万青.2008中国肿瘤登记年报[M].北京:军事医学科学出版社.2009.13—17.
  • 5Curado MP,Edwards B,Shin HR,et al.Cancer Incidencein Five Continents,Vol.Ⅸ[M].IARC Scientific Publica-tions No.160,Lyon:IARC,2008.
  • 6Parkin DM,Chen VM,Ferlay J,et al.Comparability andquality control in cancer registration[M].IARC TechnicalReport No.19,1994.
  • 7Felay J,Burkhard C,Whelan S,et al.Check and conver-sion programs for cancer registries[M].IARC TechnicalReport No.42,2005.
  • 8Felay J.The IARCcrgTools program.http://www.iacr.com.fr/iarccrgtools.htm.IACR.Lyon.2006.
  • 9Minton JP,Hoehn JL,Gerber DM,et al.Result of 400 patients CEA second look colorectal canle study[J].Cancer,1985,55(6):1 284-1 249.
  • 10Gold P,Freedman SO.Demonstration of tumor specitic antigen in human colonic carcinoma by immunological to clearance and absorption techniques[J].Jext Med,1965,121:439-462.

共引文献564

同被引文献54

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:265
  • 2孙迪文.CEA、CA125、CA153联合检测在老年乳腺恶性肿瘤患者中诊断价值分析[J].现代预防医学,2012,39(22):5839-5841. 被引量:4
  • 3曾显声,周燕斌.肺癌血清肿瘤标志物的研究现状[J].国际内科学杂志,2007,34(2):73-76. 被引量:51
  • 4M Elfagieh,F Alxla,A Gliwan,et al. Serum tumour mark- ers as a diagnostic and prognostic tool in Libyan breast cancer [J]. Turnout Biol,2012,33(6) :2371 - 2377.
  • 5MM Alegre, RA Robison, KL O' Neill. Thymidine kinase 1 up- regulation is an early event in breast tumor formation[J]. J Oncol,2012,20(12) :575647.
  • 6J Bjohle, J Bergqvist, JS Gronowitz, et al. Serum thymidine kinase activity compared with CA 15 - 3 in locally advanced and metastatic breast cancer within a randomized trial [ J]. Breast Cancer Res Treat,2013,139(3) :751 - 758.
  • 7L Carlsson, A Larsson, H Lindman. Elevated levels of thymi- dine kinase 1 peptide in serum from patients with breast can- cer[J]. Ups J Med Sci,2009,114(2):116- 120.
  • 8AC Pedersen,PD Sorensen,EH Jacobsen,et al. Sensitivity of CA 15 - 3, CEA and serum HER2 in the early detection of re- currence of breast cancer[J].Chn Chem Lab Med, 2013,51 (7) :1511 - 1519.
  • 9T Kos,S Aksoy,MA Sendur, et al. Variations in tumor marker levels in metastatie breast cancer patients according to tumorsubtypes[J]. J BUON,2013,18(3):608 - 613.
  • 10Siegel R, Naishadham D, Jemal A. Cancer statistics,2012 [ J].CA-Cancer J Clin,2012,62(1) :10 -29.

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部